Skip to main content
SpringerLink
Log in

Anaesthesia in Elderly Patients with Neurodegenerative Disorders

Special Considerations

  • Therapy In Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Neurodegenerative diseases are increasingly common in elderly patients, who present a particular anaesthetic challenge. The majority of people over the age of 70 years have some degree of cerebral atrophy. The pathogenesis of neurodegenerative diseases is due to alterations in the transport, degradation and aggregation of proteins. Alterations in physiology that occur with advancing age affect both the pharmacokinetics and pharmacodynamics of drugs used in the elderly. Changes in pharmacokinetics result in either increased or reduced drug concentrations depending on the variable contributions of absorption, metabolism and elimination. The distribution of a drug depends on its protein binding, cardiac output and blood volume, which are all altered in the elderly. Metabolism and excretion of drugs are also affected due to changes in hepatic and renal mass and blood flow in the elderly.

A number of drugs are used in neurodegenerative disorders including antidepressants, benzodiazepines, antipsychotics, acetylcholinesterase inhibitors and levodopa. Polypharmacy is a common problem, which can lead to adverse drug interactions and an exacerbation of dementia. Levodopa, bromocriptine and tricyclic antidepressants are known to cause orthostatic hypotension in patients with neurodegenerative disease. Elderly patients are liable to excessive sedation from benzodiazepines in both the pre- and postoperative period; therefore these drugs should be prescribed in low doses. For induction of general anaesthesia propofol is a suitable agent in patients with neurodegenerative disease due to its rapid metabolism, but may not be suitable in patients with Parkinson’s disease as it can induce spontaneous involuntary movements. Volatile inhalational agents should be administered carefully in the elderly, as they are more sensitive to the depressant cerebral and cardiovascular effects. Levodopa should be avoided in conjunction with halothane, which sensitises the heart to catecholamines. Co-administration of monoamine oxidase inhibitors and opioids should be avoided as it can cause agitation, muscular rigidity, sweating and hyperpyrexia. If an anticholinergic agent is required, then glycopyrronium bromide is the drug of choice in this group of patients, as it does not cross the blood brain barrier.

Patients should continue to take their usual medications in hospital and do not let the change in routine alter the times at which treatments are administered. This is particularly relevant to the timing of levodopa in Parkinson’s disease, as missed treatment can be detrimental. Regional anaesthesia may, however, have significant advantages in patients with Parkinson’s disease, who can continue to take oral levodopa preoperatively, during surgery, if required, and early in the postoperative period. Anti-emetic drugs such as phenothiazines, butyrophenones and metoclopramide should be used carefully in the postoperative period in these patients as their antidopaminergic effects may induce or exacerbate parkinsonian effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. World population prospects: 2000 revision. New York: Population Division, Department of Economic and Social Affairs, United Nations, 2000: 14–6

  2. National Confidential Enquiry into Perioperative Deaths. Extremes of age. London: NCEPOD, 1999: 59

    Google Scholar 

  3. LeMay M. Radiologic changes of the aging brain and skull. AJR Am J Roentgenol 1984; 143: 383–9

    PubMed  CAS  Google Scholar 

  4. Katzman R. Medical progress: Alzheimer’s disease. N Engl J Med 1986; 314: 964–71

    Article  PubMed  CAS  Google Scholar 

  5. Prusiner SB. Shattock lecture: neurodegenerative diseases and prions. N Engl J Med 2001; 344: 1516–26

    Article  PubMed  CAS  Google Scholar 

  6. Perry EK, Martin-Ruiz CM, Court JA. Nicotinic receptor subtypes in human brain related to aging and dementia. Alcohol 2001; 24: 63–8

    Article  PubMed  CAS  Google Scholar 

  7. Nakamura S, Takahashi T, Yamashita H, et al. Nicotinic acetylcholine receptors and neurodegenerative disease. Alcohol 2001; 24: 79–81

    Article  PubMed  CAS  Google Scholar 

  8. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer’s disease in a community population. JAMA 1995; 273: 1354–9

    Article  PubMed  CAS  Google Scholar 

  9. Ott A, Breteler MMB, van Harskamp F, et al. Prevalence of Alzheimer’s disease and vascular dementia: association with education: the Rotterdam Study. BMJ 1995; 310: 970–3

    Article  PubMed  CAS  Google Scholar 

  10. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551–6

    Article  PubMed  CAS  Google Scholar 

  11. Pfeffer RI, Afifi AA, Chance JM. Prevalence of Alzheimer’s disease in a retirement community. Am J Epidemiol 1987; 125: 420–36

    PubMed  CAS  Google Scholar 

  12. Kuusisto J, Koivisto K, Kervinen K, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer’s disease: population based study. BMJ 1994; 309: 636–8

    Article  PubMed  CAS  Google Scholar 

  13. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993; 261: 921–3

    Article  PubMed  CAS  Google Scholar 

  14. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E 84 with late-onset familial and sporadic Alzheimer’s disease. Lancet 1993; 342: 710–1

    Article  PubMed  CAS  Google Scholar 

  15. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993; 342: 697–9

    Article  PubMed  CAS  Google Scholar 

  16. Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E 84 allele and the lifetime risk of Alzheimer’s disease: what physicians know, and what they should know. Arch Neurol 1995; 52: 1074–9

    Article  PubMed  CAS  Google Scholar 

  17. Mortimer JA, van Duijn CM, Chandra V, et al. Head trauma as a risk factor for Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991; 20Suppl. 2: S28–35

    Article  PubMed  Google Scholar 

  18. Breteler MMB, van Duijn CM, Chandra V, et al. Medical history and the risk of Alzheimer’s disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991; 20Suppl. 2: S36–42

    Article  PubMed  Google Scholar 

  19. Stern Y, Gurland B, Thomas K, et al. Influence of education and occupation on the incidence of Alzheimer’s disease. JAMA 1994; 271: 1004–10

    Article  PubMed  CAS  Google Scholar 

  20. Fratiglioni L, Wang H-X. Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies. Behav Brain Res 2000; 113: 117–20

    Article  PubMed  CAS  Google Scholar 

  21. George AE, Leon MJ, Rosenbloom S, et al. Ventricular volume and cognitive deficit: a computed tomographic study. Radiology 1983; 149: 493–8

    PubMed  CAS  Google Scholar 

  22. Richards M, Touchon J, Ledesert B, et al. Mild extrapyramidal signs and functional impairment in ageing. Int J Geriatr Psychiatry 2002; 17: 150–3

    Article  PubMed  Google Scholar 

  23. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334: 71–6

    Article  PubMed  CAS  Google Scholar 

  24. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000; 54: 1596–603

    Article  PubMed  CAS  Google Scholar 

  25. Levy G, Tang M-X, Louis ED, et al. The association of incident dementia with mortality in Parkinson’s disease. Neurology 2002; 59: 1708–13

    Article  PubMed  CAS  Google Scholar 

  26. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson’s disease. Neurology 2002; 58: 179–85

    Article  PubMed  Google Scholar 

  27. Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45: 577–82

    Article  PubMed  CAS  Google Scholar 

  28. Maat-Kievit A, Losekoot M, Zwinderman K, et al. Predictability of age at onset in Huntington disease in the Dutch population. Medicine 2002; 81: 251–9

    Article  PubMed  CAS  Google Scholar 

  29. Myers RH, Sax DS, Schoenfeld M, et al. Late onset of Huntington’s disease. J Neurol Neurosurg Psychiatry 1985; 48: 530–4

    Article  PubMed  CAS  Google Scholar 

  30. Collins S, Boyd A, Fletcher A, et al. Novel prion protein gene mutation in an octogenarian with Creutzfeldt-Jakob disease. Arch Neurol 2000; 57: 1058–63

    Article  PubMed  CAS  Google Scholar 

  31. de Silva R, Findlay C, Awad I, et al. Creutzfeldt-Jakob disease in the elderly. Postgrad Med J 1997; 73: 557–9

    Article  PubMed  Google Scholar 

  32. Cousens SN, Zeidler M, Esmonde TF, et al. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970–96. BMJ 1997; 315: 389–95

    Article  PubMed  CAS  Google Scholar 

  33. McLachlan MSF. The ageing kidney. Lancet 1978; II: 143–5

    Article  Google Scholar 

  34. Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver flow in healthy man. Hepatology 1989; 9: 297–301

    Article  PubMed  CAS  Google Scholar 

  35. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363–9

    Article  PubMed  CAS  Google Scholar 

  36. Nolan L, O’Malley K. Prescribing for the elderly (Part I): sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142–9

    PubMed  CAS  Google Scholar 

  37. Mamdani MM, Parikh SV, Austin PC, et al. Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 2000; 157: 360–7

    Article  PubMed  CAS  Google Scholar 

  38. Mittmann N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 1997; 46: 191–217

    Article  PubMed  CAS  Google Scholar 

  39. Kirby M, Denihan A, Bruce I, et al. Benzodiazepine use among the elderly in the community. Int J Geriatr Psychiatry 1999; 14: 280–4

    Article  PubMed  CAS  Google Scholar 

  40. Castleden CM, George CF, Marcer D, et al. Increased sensitivity to nitrazepam in old age. BMJ 1977; I: 10–2

    Article  Google Scholar 

  41. van Dijk KN, de Vries CS, ter Huurne K, et al. Concomitant prescribing of benzodiazepines during antidepressant therapy in the elderly. J Clin Epidemiol 2002; 55: 1049–53

    Article  PubMed  Google Scholar 

  42. Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced Parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 1999; 19: 322–8

    Article  PubMed  CAS  Google Scholar 

  43. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155: 1521–8

    PubMed  CAS  Google Scholar 

  44. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37: 1368–73

    Article  PubMed  CAS  Google Scholar 

  45. Rösier M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international, randomised controlled trial. BMJ 1999; 318: 633–40

    Google Scholar 

  46. Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer’s disease. Gerontology 1999; 45: 15–22

    Article  PubMed  CAS  Google Scholar 

  47. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association and the American Geriatrics Society. JAMA 1997; 278: 1363–71

    Article  PubMed  CAS  Google Scholar 

  48. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1977; I(8007): 345–9

    Article  Google Scholar 

  49. Koller WC. Neuroprotection for Parkinson’s disease. Ann Neurol 1998; 44: S155–9

    Article  PubMed  CAS  Google Scholar 

  50. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–71

    Article  Google Scholar 

  51. Münchau A, Bhatia KP. Pharmacological treatment of Parkinson’s disease. Postgrad Med J 2000; 76: 602–10

    Article  PubMed  Google Scholar 

  52. Orr HT, Zoghbi HY. Reversing neurodegeneration: a promise unfolds. Cell 2000; 101: 1–4

    Article  PubMed  CAS  Google Scholar 

  53. Rabins PV, Folstein MF. Delirium and dementia: diagnostic criteria and fatality rates. Br J Psychiatry 1982; 140: 149–53

    Article  PubMed  CAS  Google Scholar 

  54. Larson EB, Kukull WA, Buchner D, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987; 107: 169–73

    PubMed  CAS  Google Scholar 

  55. Bohnen N, Warner MA, Kokmen E, et al. Early and midlife exposure to anesthesia and age of onset of Alzheimer’s disease. Int J Neurosci 1994; 77: 181–5

    Article  PubMed  CAS  Google Scholar 

  56. Bone I, Rosen M. Alzheimer’s disease and anaesthesia. Anaesthesia 2000; 55: 592–3

    Article  PubMed  CAS  Google Scholar 

  57. Bohnen NI, Warner MA, Kokmen E, et al. Alzheimer’s disease and cumulative exposure to anesthesia: a case-control study. J Am Geriatr Soc 1994; 42: 198–201

    PubMed  CAS  Google Scholar 

  58. Gasparini M, Vanacore N, Schiaffini C, et al. A case-control study on Alzheimer’s disease and exposure to anesthesia. Neurol Sci 2002; 23: 11–4

    Article  PubMed  CAS  Google Scholar 

  59. Parikh SS, Chung F. Postoperative delirium in the elderly. Anesth Analg 1995; 80: 1223–32

    PubMed  CAS  Google Scholar 

  60. Hanning CD, Blokland A, Johnson M, et al. Effects of repeated anaesthesia on central cholinergic function in elderly rats [abstract]. Br J Anaesth 2000; 85: 641P

    Google Scholar 

  61. Muravchick S, Smith DS. Parkinsonian symptoms during emergence from general anesthesia. Anesthesiology 1995; 82: 305–7

    Article  PubMed  CAS  Google Scholar 

  62. Hutchinson RC, Sugden JC. Anaesthesia for Shy-Drager syn-drome. Anaesthesia 1984; 39: 1229–31

    Article  PubMed  CAS  Google Scholar 

  63. Vincken WG, Gauthier SG, Dollfuss RE, et al. Involvement of upper-airway muscles in extrapyramidal disorders: a cause of airflow limitation. N Engl J Med 1984; 311: 438–42

    Article  PubMed  CAS  Google Scholar 

  64. Easdown LJ, Tessler MJ, Minuk J. Upper airway involvement in Parkinson’s disease resulting in postoperative respiratory failure. Can J Anaesth 1995; 42: 344–7

    Article  PubMed  CAS  Google Scholar 

  65. Wada H, Nakajoh K, Satoh-Nakagawa T, et al. Risk factors of aspiration pneumonia in Alzheimer’s disease patients. Gerontology 2001; 47: 271–6

    Article  PubMed  CAS  Google Scholar 

  66. Kobayashi H, Nakagawa T, Sekizawa K, et al. Levodopa and swallowing reflex. Lancet 1996; 348: 1320–1

    Article  PubMed  CAS  Google Scholar 

  67. Gustafson Y, Brännström B, Norberg A, et al. Underdiagnosis and poor documentation of acute confusional states in elderly hip fracture patients. J Am Geriatr Soc 1991; 39: 760–5

    PubMed  CAS  Google Scholar 

  68. Rasmussen LS, Steentoft A, Kristensen PA, et al. Benzodiazepines and postoperative cognitive dysfunction in the elderly. Br J Anaesth 1999; 83: 585–9

    Article  PubMed  CAS  Google Scholar 

  69. Pain L, Jeltsch H, Lehmann O, et al. Central cholinergic depletion induced by 192 IgG-saporin alleviates the sedative effects of propofol in rats. Br J Anaesth 2000; 85: 869–73

    Article  PubMed  CAS  Google Scholar 

  70. Krauss JK, Akeyson EW, Giam P, et al. Propofol-induced dyskinesias in Parkinson’s disease. Anesth Analg 1996; 83: 420–2

    PubMed  CAS  Google Scholar 

  71. Anderson BJ, Marks PV, Futter ME. Propofol: contrasting effects in movement disorders. Br J Neurosurg 1994; 8: 387–8

    Article  PubMed  CAS  Google Scholar 

  72. Mantz J, Varlet C, Lecharny J-B, et al. Effects of volatile anesthetics, thiopental, and ketamine on spontaneous and depolarization-evoked dopamine release from striatal synaptosomes in the rat. Anesthesiology 1994; 80: 352–63

    Article  PubMed  CAS  Google Scholar 

  73. Mackenzie N, Grant IS. Comparison of the new emulsion formulation of propofol with methohexitone and thiopentone for induction of anaesthesia in day cases. Br J Anaesth 1985; 57(8): 725–31

    Article  PubMed  CAS  Google Scholar 

  74. Hetherington A, Rosenblatt RM. Ketamine and paralysis agitans [letter]. Anesthesiology 1980; 52: 527

    Article  PubMed  CAS  Google Scholar 

  75. Conzen P, Peter K. Inhalational anaesthesia at the extremes of age: geriatric anaesthesia. Anaesthesia 1995; 50 Suppl.: 29–33S

    Article  PubMed  Google Scholar 

  76. Gravlee GP. Succinylcholine-induced hyperkalemia in a patient with Parkinson’s disease. Anesth Analg 1980; 59: 444–6

    Article  PubMed  CAS  Google Scholar 

  77. Muzzi DA, Black S, Cucchiara RF. The lack of effect of succinylcholine on serum potassium in patients with Parkinson’s disease [letter]. Anesthesiology 1989; 71: 322

    Article  PubMed  CAS  Google Scholar 

  78. Wali FA. Myorelaxant effect of diazepam: interactions with neuromuscular blocking agents and cholinergic drugs. Acta Anaesthesiol Scand 1985; 29: 785–9

    Article  PubMed  CAS  Google Scholar 

  79. Driessen JJ, Vree TB, van Egmond J, et al. Interaction of midazolam with two non-depolarising neuromuscular blocking drugs in the rat in vivo sciatic nerve-tibialis anterior muscle preparation. Br J Anaesth 1985; 57: 1089–94

    Article  PubMed  CAS  Google Scholar 

  80. Driessen JJ, Crul JF, Vree TB, et al. Benzodiazepines and neuromuscular blocking drugs in patients. Acta Anaesthesiol 1986; 30: 642–6

    Article  CAS  Google Scholar 

  81. Mets B. Acute dystonia after alfentanil in untreated Parkinson’s disease. Anesth Analg 1991; 72: 557–8

    Article  PubMed  CAS  Google Scholar 

  82. Berg D, Becker G, Reiners K. Reduction of dyskinesia and induction of akinesia induced by morphine in two Parkinsonian patients with severe sciatica. J Neural Transm 1999; 106: 725–8

    Article  PubMed  CAS  Google Scholar 

  83. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 1991; 337: 246

    Article  PubMed  CAS  Google Scholar 

  84. Fischer SP, Mantin R, Brock-Utne JG. Ketorolac and propofol anesthesia in a patient taking chronic monamine oxidase inhibitors. J Clin Anesth 1996; 8: 245–7

    Article  PubMed  CAS  Google Scholar 

  85. Tune LE, Damlouji NF, Holland A, et al. Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet 1981; II: 651–3

    Article  Google Scholar 

  86. Miller PS, Richardson JS, Jyu CA, et al. Association of low serum anticholinergic levels and cognitive impairment in elderly presurgical patients. Am J Psychiatry 1988; 145: 342–5

    PubMed  CAS  Google Scholar 

  87. Smith DS, Orkin FK, Gardner SM, et al. Prolonged sedation in the elderly after intraoperative atropine administration. Anesthesiology 1979; 51: 348–9

    Article  PubMed  CAS  Google Scholar 

  88. Sheref SE. Pattern of CNS recovery following reversal of neuromuscular blockade: comparison of atropine and glycopyrrolate. Br J Anaesth 1985; 57: 188–91

    Article  PubMed  CAS  Google Scholar 

  89. Furuya R, Hirai A, Andoh T, et al. Successful perioperative management of a patient with Parkinson’s disease by enterai Levodopa administration under propofol anesthesia. Anesthesiology 1998; 89: 261–3

    Article  PubMed  CAS  Google Scholar 

  90. Chung FF, Chung A, Meier RH, et al. Comparison of perioperative mental function after general anaesthesia and spinal anaesthesia with intra-venous sedation. Can J Anaesth 1989; 36: 382–7

    Article  PubMed  CAS  Google Scholar 

  91. Crul BJP, Hulstijn W, Burger IC. Influence of the type of anaesthesia on post-operative subjective physical well-being and mental function in elderly patients. Acta Anaesthesiol Scand 1992; 36: 615–20

    Article  PubMed  CAS  Google Scholar 

  92. Neilson WR, Gelb AW, Casey JE, et al. Long-term cognitive and social sequelae of general versus regional anesthesia during arthroplasty in the elderly. Anesthesiology 1990; 73: 1103–9

    Article  Google Scholar 

  93. Williams-Russo P, Sharrock NE, Mattis S, et al. Cognitive effects after epidural vs general anesthesia in older adults: a randomised trial. JAMA 1995; 274: 44–50

    Article  PubMed  CAS  Google Scholar 

  94. Berggren D, Gustafson Y, Eriksson B, et al. Postoperative confusion after anesthesia in elderly patients with femoral neck fractures. Anesth Analg 1987; 66: 497–504

    Article  PubMed  CAS  Google Scholar 

  95. Reed AP, Han DG. Intraoperative exacerbation of Parkinson’s disease. Anesth Analg 1992; 75: 850–3

    Article  PubMed  CAS  Google Scholar 

  96. Bedford PD. Adverse cerebral effects of anaesthesia on old people. Lancet 1955; II: 259–63

    Article  Google Scholar 

  97. Gustafson Y, Berggren D, Brännström B, et al. Acute confusional states in elderly patients treated for femoral neck fracture. J Am Geriatr Soc 1988; 36: 525–30

    PubMed  CAS  Google Scholar 

  98. O’Keeffe ST, Chonchubhair AN. Postoperative delirium in the elderly. Br J Anaesth 1994; 73: 673–87

    Article  PubMed  Google Scholar 

  99. Golden WE, Lavender RC, Metzer WS. Acute postoperative confusion and hallucinations in Parkinson disease. Ann Intern Med 1989; 111: 218–22

    PubMed  CAS  Google Scholar 

  100. Levkoff SE, Evans DA, Liptzin B, et al. Delirium: the occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med 1992; 152: 334–40

    Article  PubMed  CAS  Google Scholar 

  101. Dijkstra JB, Houx PJ, Jolies J. Cognition after major surgery in the elderly: test performance and complaints. Br J Anaesth 1999; 82: 867–74

    Article  PubMed  CAS  Google Scholar 

  102. Ancelin M-L, de Roquefeuil G, Ledésert B, et al. Exposure to anaesthetic agents, cognitive functioning and depressive symptomatology in the elderly. Br J Psychiatry 2001; 178: 360–6

    Article  PubMed  CAS  Google Scholar 

  103. Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term postoperative cognitive dysfunction in the elderly: ISPOCD1 study. Lancet 1998; 351: 857–61

    Article  PubMed  CAS  Google Scholar 

  104. Gustafson Y, Brännstöm B, Berggren D, et al. A geriatricanesthesiologic program to reduce acute confusional states in elderly patients treated for femoral neck fractures. J Am Geriatr Soc 1991; 39: 655–62

    PubMed  CAS  Google Scholar 

  105. Gualandi W, Bonfanti G. A case of prolonged apnoea in Huntington’s chorea. Acta Anaesthesiol 1968; 19: 235–8

    PubMed  Google Scholar 

  106. Davies DD. Abnormal response to anaesthesia in a case of Huntington’s chorea. Br J Anaesth 1966; 38: 490–1

    Article  PubMed  CAS  Google Scholar 

  107. Rodrigo MRC. Huntington’s chorea: midazolam, a suitable induction agent? Br J Anaesth 1987; 59: 388–9

    Article  PubMed  CAS  Google Scholar 

  108. Leng CP, Gupta K. Huntington’s chorea. Br J Anaesth 2001; 86: 154–5

    PubMed  CAS  Google Scholar 

  109. Nagele P, Hammerle AF. Sevoflurane and mivacurium in a patient with Huntington’s chorea. Br J Anaesth 2000; 85: 320–1

    Article  PubMed  CAS  Google Scholar 

  110. Jin F, Chung F. Minimizing perioperative adverse events in the elderly. Br J Anaesth 2001; 87: 608–24

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Anaesthesia, St George’s Hospital Medical School, University of London, Jenner Wing, Cranmer Terrace, London, SW17 ORE, England

    Deborah A. Burton, Grainne Nicholson & George M. Hall

Authors
  1. Deborah A. Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grainne Nicholson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George M. Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah A. Burton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burton, D.A., Nicholson, G. & Hall, G.M. Anaesthesia in Elderly Patients with Neurodegenerative Disorders. Drugs Aging 21, 229–242 (2004). https://doi.org/10.2165/00002512-200421040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200421040-00002

Keywords

Search

Navigation